(¿Â¶óÀÎ) 2020³â Á¦61Â÷ ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ(¿Â¶óÀÎ)-11¿ù 7ÀÏ : 2020-11-07±³À°ÀÏÀÚ : 2020-11-07
±³À°Àå¼Ò : ¿Â¶óÀÎ °³ÃÖ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2020³â Á¦61Â÷ ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ(¿Â¶óÀÎ)-11¿ù 7ÀÏ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ±èÇìÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 2 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í Àü¹®ÀÇ 20,000¿ø, Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø ¹× ±âŸ 10,000¿ø, ºñȸ¿ø 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 07ÀÏ Room A 10:00~10:30 FLT3 inhibitors & Bcl-2 inhibitor for adult AML Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11¿ù 07ÀÏ Room A 10:30~11:00 FLT3 inhibitors & HMA for pediatric AML À¯°ÇÈñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11¿ù 07ÀÏ Room A 11:00~11:30 What comes next to HMA for MDS? ±èÀ¯Áø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11¿ù 07ÀÏ Room A 11:30~12:00 Multi parameterflow cytometry for AML/MDS ¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë)